Who is sponsoring NCT04608084?

NCT04608084 is sponsored by University Health Network, Toronto.

What condition does NCT04608084 study?

NCT04608084 studies Ocular Surface Disease, Dry Eye Syndromes.

What drugs are being tested in NCT04608084?

Interventions: Autologous platelet rich plasma eye drops.

What is the status of NCT04608084?

NCT04608084 is currently UNKNOWN.

Last reviewed 2020-10-22 · How we verify

Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease

NCT04608084 Phase 4 UNKNOWN

The purpose of this study is to evaluate prospectively the efficacy of topical administration of autologous platelet rich plasma as monotherapy for the treatment of symptoms and clinical signs in cases affected by moderate to severe forms of ocular surface disease

Details

Lead sponsor	University Health Network, Toronto
Phase	Phase 4
Status	UNKNOWN
Enrolment	100
Start date	2021-01
Completion	2023-01

Conditions

Ocular Surface Disease
Dry Eye Syndromes

Interventions

Autologous platelet rich plasma eye drops

Primary outcomes

Mean change from baseline in Ocular Surface Disease Index (OSDI) score questionnaire — At 6 and 12 weeks visit
The OSDI assesses quality of life measures of ocular surface disease symptoms which aligns the questionnaire with Federal Food and Drug Administration's emphasis on utilizing patient-reported outcomes in order to support medicinal product submissions and clinical drug trial efficacy

Countries

Canada